NEW HAVEN, Conn., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
(Nasdaq:ACHN) today announced that it plans to report second quarter 2017 financial results on Tuesday, August 8, 2017, after the
markets close. Achillion will also host a conference call and live webcast to discuss these results and to provide an update on the
Company’s factor D inhibitor platform, including Achillion’s novel first-in-class oral compound, ACH-4471. The conference call will
be held at 4:05 p.m. ET.
A live audio webcast of the call and accompanying slides will be accessible at http://www.achillion.com or http://ir.achillion.com. Please connect to Achillion's website several minutes prior to the
start of the broadcast to ensure adequate time for any software download that may be necessary. To participate in the conference
call, please dial (866) 205-4820 in the U.S. or (419) 386-0004 for international callers.
A replay of the webcast will be available for 30 days on http://www.achillion.com. Alternatively, a telephonic replay of the conference call will be
available starting at 8:00 p.m. ET on August 8, 2015, through 7:05 p.m. ET on August 12, 2017 by dialing (855) 859-2056 or (404)
537-3406. The replay passcode is 63792663.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage
its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with
serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue
best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement factor D
inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company
with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors & Media: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 gschulman@achillion.com
